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A B S T R A C T
Membrane proteins exist in lipid bilayers and mediate solute transport, signal transduction, cell-cell commu-
nication and energy conversion. Their activities are fundamental for life, which make them prominent subjects of
study, but access to only a limited number of high-resolution structures complicates their mechanistic under-
standing. The absence of such structures relates mainly to difficulties in expressing and purifying high quality
membrane protein samples in large quantities. An additional layer of complexity stems from the presence of
intra- and/or extra-cellular domains constituted by unstructured intrinsically disordered regions (IDR), which
can be hundreds of residues long. Although IDRs form key interaction hubs that facilitate biological processes,
these are regularly removed to enable structural studies. To advance mechanistic insight into intact intrinsically
disordered membrane proteins, we have developed a protocol for their purification. Using engineered yeast cells
for optimized expression and purification, we have purified to homogeneity two very different human membrane
proteins each with> 300 residues long IDRs; the sodium proton exchanger 1 and the growth hormone receptor.
Subsequent to their purification we have further explored their incorporation into membrane scaffolding protein
nanodiscs, which will enable future structural studies.
1. Introduction
Integral membrane proteins (MP) constitute around 30% of the
proteome [1] and they are fundamental for homeostatic maintenance of
living cells, which involves a controlled flow of water and substrates
across cellular membranes and signal transduction through MP re-
ceptors. Knowledge on MP structures has in the past decades been
crucial for improving our mechanistic understanding of fundamental
cellular processes and for rational drug design [2,3] as MPs con-
stitute> 60% of known drug targets [4]. However, relative to soluble
proteins, MP structures are heavily underrepresented in the Protein
Data Bank (PDB). Only a small subset (~14%) of known MP structures
are of human origin [5,6]. Prokaryotic protein, which are easier to
purify due to their shorter extramembrane regions, have consequently
been used extensively to model human MPs [7]. This approach is lim-
ited by the fact that around 85% of human MPs lack prokaryotic
counterparts [8]. The recent technical innovations in cryo-EM [9] and
MP crystallography [10] have made structures of human MPs more
accessible. Although most MPs that are currently targeted
therapeutically belong to the group of G-protein coupled receptors, they
represent only a fraction of the MP continuum. Single pass receptors
and multi-spanning MPs, like transporters, pumps and channels, play
pivotal roles both physiologically and in pathophysiology, and re-
present an understudied area in structural biology. This limits devel-
opment of drugs targeting these MP classes [11]. One reason for their
structural absence is likely to be found outside the membrane and is
related to their extra-membranous domain(s), of which both folded and
intrinsically disordered domains exist. Two human examples where an
intact structure is lacking and which harbor significant extra-membra-
neous parts, are the sodium-proton exchanger 1 (hNHE1) [12] and the
single-pass cytokine receptor, the growth hormone receptor (hGHR)
[13]. hNHE1 contains 12 transmembrane helices but also contains ex-
tensive disordered loops and a long, disordered C-terminal tail. hGHR
has only 4% of its sequence embedded in the membrane and has a long,
disordered intracellular domain. These are issues that complicate re-
combinant production and purification.
hNHE1 belongs to the SLC9A family and is involved in numerous
essential physiological processes [12,14,15]. hNHE1 dysregulation is
https://doi.org/10.1016/j.bbamem.2020.183272
Received 23 November 2019; Received in revised form 8 March 2020; Accepted 9 March 2020
⁎ Corresponding authors.
E-mail addresses: PAPedersen@bio.ku.dk (P.A. Pedersen), bbk@bio.ku.dk (B.B. Kragelund).
BBA - Biomembranes 1862 (2020) 183272
Available online 10 March 2020
0005-2736/ © 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license 
(http://creativecommons.org/licenses/BY/4.0/).
T
associated with severe diseases including cancer [16], rendering it an
interesting therapeutic target. Its primary function is to maintain cy-
tosolic pH homeostasis by 1:1 exchange of extracellular sodium ions for
cytosolic protons. hNHE1 activity is tightly regulated through lipid-
binding partners, phosphorylation and interactions with multiple pro-
teins through its intrinsically disordered C-terminal tail [12,17,18]. No
high-resolution structures exist from any member of the SLC9A family.
Models based on bacterial homologs predict a short intracellular N-
terminus, 12 transmembrane (TM) helices and a long, partially in-
trinsically disordered (ID) C-terminal cytoplasmic tail [12], (Fig. 1A).
hGHR is a class 1 cytokine receptor, which regulates key physiolo-
gical processes such as growth at a cellular and systemic level, meta-
bolism, bone turnover and the immune system [19–21]. It has an ex-
tracellular domain (ECD), one TM helix i.e. the transmembrane domain
(TMD) and a long ID intracellular domain (ICD) (Fig. 1B). Intracellular
signaling is initiated by growth hormone binding to the ECD in a 2:1
stoichiometry [22]. Even though the hGHR has been heavily studied for
more than three decades, and three-dimensional structures exist of the
smaller, globular domains [23,24], no experimentally determined full-
length structure exists for this or any other class 1 cytokine-receptor,
although a combined experimental and computational model of the
prolaction receptor exists [25]. Furthermore, hGHR dysregulation is
associated with severes diseases including lung cancer [26], which
makes hGHR an important therapeutic drug target.
MPs are notoriously difficult to purify as their native abundance is
typically prohibitively low. They are largely understood in terms of
well-defined structures and are unlikely to be disordered in a classical
sense. However, several MPs contain intrinsic disordered regions
(IDRs), often a tail or loop that can be> 300 residues long [12,27–29].
The different physico-chemical properties of the membrane embedded
part, the water soluble globular part and the IDR make them difficult to
purify and prone to degradation. Moreover, despite the strengths of
cryo-EM and crystallography, these come short in elucidating IDRs
within MPs. Thus, MPs with IDRs appear method-orphan in high-re-
solution structural biology. Instead, low-resolution techniques such as
small angle x-ray and neutron scattering (SAXS/SANS) could emerge as
a golden standard [30,31]. Studies of MPs within lipid environments
have advanced in recent years by developments of the nanodisc tech-
nology highly applicable to SAXS/SANS [32,33]. Nanodiscs are deri-
vatives of Apo-A1 containing only its lipid-binding helical-repeat do-
main [33]. They are amphiphilic membrane scaffold proteins (MSP)
that form soluble discoidal particles in the presence of lipids [34,35],
with the most utilized MSP being MSP1D1 [32]. Studying MPs in na-
nodiscs allows a detergent-free environment with no empty detergent
micelles complicating scattering data processing.
In light of these unmet needs, we take advantage of a newly de-
veloped expression system in the yeast S. cerevisiae, which has the ca-
pacity to produce large amounts of high-quality MPs [36,37]. This
system includes a yeast that features increased plasmid copy numbers
from 20 to 200 per cell prior to induction of recombinant protein
production, regulated by a galactose inducible promoter. The PAP1500
host strain overexpresses the Gal4 transcription factor concomitantly
with recombinant protein production [38]. Target protein genes are
codon optimized for S. cerevisiae and produced with a C-terminal yeast-
enhanced GFP (yeGFP) TEV-yeGFP-His10-tag, suitable for expression
and purification optimization. Using this system, a number of human
MPs have been purified to homogeneity including aquaporin 10
(AQP10) [39], transient receptor (TRP) channels [40], the chloride
channel CLC-1 [41] and the Ether-a-go-go-related gene (hERG) po-
tassium channel [42] with structure determination of human AQP10
(PDB entry 6F7H) [39] and human CLC-1 (PDB entry 6QVC) [41] by x-
ray crystallography and cryo-EM, respectively [39,41]. However,
common to these structures is that the major parts are fully membrane
embedded or is ordered outside of the membrane (AQP10: 84%, CLC-1:
Fig. 1. Cartoons of the human sodium proton exchanger 1 (hNHE1) and the human growth hormone receptor (hGHR). (A) hNHE1 and its 12 transmembrane helices
in a lipid bilayer followed by the long C-terminal disordered tail. (B) The full-length hGHR in a lipid bilayer showing its extra-cellular domain, its transmembrane
helix and disordered C-terminal tail. (C) Overview of steps from MP expression tests to pure MP incorporated into a nanodisc. The blue arrows from I to V indicate the
steps in chronological order. I: Expression test; II: Lysing cells and isolation of crude membranes; III: Detergent screen and FSEC analysis; IV: Large scale purification;
V: Incorportation of the MP into nanodiscs. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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81%). The aim of this work, therefore, was to provide a suitable pro-
tocol for producing intact MPs with long disordered regions for sub-
sequent structural studies. We first survey the abundance and length of
disordered regions in human MPs and find that disordered N- and C-
terminals appear frequently in the human transmembrane proteome.
We then devise a method to express and purify high quality intact
human MP including intact long disordered ICDs, using hNHE1 and
hGHR as examples (Fig. 1C). In addition to solubilization in detergents,
we show that hGHR can be reconstituted into native-like membrane
environments with the use of nanodisc technology. Our work lays the
framework for future studies of these proteins by SAXS/SANS and cryo-
EM, and highlights the need for developing even larger nanodisc sys-
tems.
2. Materials and methods
2.1. Disorder prediction of human MPs
Dobson et al. predicts that 26% of the human proteome consists of
MPs and annotate the sequences that are experimentally confirmed and
predicted sequences with high likelihood of being human MPs. As of
September 2019, the human transmembrane protein (HTP) database
(http://htp.enzim.hu) consists of 5308 sequences [43]. These sequences
were applied to the machine learning algorithm Disopred3 (version
3.16) [44]. The algorithm takes a sequence alignment as input. For each
sequence we created an alignment using blast (version 2.2.26) [45]
with uniref90 as the sequence database [46]. Disopred3 gives a disorder
score (between zero and one) per amino acid and labels individual
residues “disordered” if the score is equal to or above 0.5 and ordered if
below 0.5. To prevent inconsistent segments of ordered and disordered
regions, scores were “smoothened” by averaging the scores in a sliding
window of 3 in size. After prediction, the number of disordered residues
in the N- and C-terminal was counted and grouped.
2.2. Expression system and plasmid constructs
Recombinant hNHE1 and hGHR were produced in S. cerevisiae strain
PAP1500 (α ura3-52 trp1::GAL10-GAL4 lys2-801 leu2Δ1 his3Δ200
pep4::HIS3prb1Δ1.6 R can1 GAL) [47]. Codon optimized human hNHE1
and hGHR cDNAs for S. cerevisiae were purchased from Genscript, USA.
Both hNHE1 and hGHR were C-terminally tagged with a Tobacco Etch
Virus cleavage site and yEGFP-His10 sequence by PCR amplifying each
codon optimized cDNA with the following primers:
hGHR_FW:
5’-TTACTATACTTCTATAGAGACGCAAAGAGAAATAGTAAGATA
ATTATGGATTTATGGCAATTATTATTAACTTTAGCTTTAGCTGGTTCT
TCTGATGCT TTTTCTGGTTCAGAAGCTACT-3’
hGHR_RV:
5’-AAATTGACTTTGAAAATACAAATTTTCAGAGTAACCCTTCAATG
CAAC-3’
hNHE1_FW:
5’-TTACTATACTTCTATAGAGACGCAAAGAGAAATAGTAAGATAAT
TATGGTTTTGAGATCTGGTATCT-3’
hNHE1_RV:
5’-AAATTGACTTTGAAAATACAAATTTTCTTGACCTTTTGGGAAAA
ATGGT-3’
yeGFP_FW
5-GAAAATTTGTATTTTCAAAGTCAATTTATGAGTAAGGGTGAAGA
ATTATT
yeGFP_RV:
5’ GGGCGTGAATCTAAGCGTGACATAACTAATTACATCTAATGGTG
ATGGTGATGGTGATGGTGATGGTGTTTATATAATTCATCCATACCGT
GAG –3’
For hNHE1 and hGHR the underlined sequences are used for in vivo
homologous recombination with the expression plasmid and the bold
sequence is for recombination with the yeGFP3 [48] PCR fragment to
generate expression plasmids directly in the S. cerevisiae expression
strain PAP1500. The bold and underlined sequence is the addition of
the hGHR signal peptide. The italicized sequence is the Kozak sequence
from the yeast PMR1 gene. For yeGFP, the bold sequence is for re-
combination with the anti-codon TEV site. The underlined sequence is
used for in vivo homologous recombination. The italicized CTA is re-
verse complementary to the translational stop codon. The sequence in
bold font encodes the His10-tag.
2.3. Temperature optimization of hGHR and hNHE1 production
Yeast cells from a glycerol stock were transferred to 5 mL Synthetic
Defined (SD) medium (2% (w/v) glucose, 38 mM (NH4)2SO4, 6.4 mM
KH2PO4, 0.7 mM K2HPO4, 2 mM MgSO4, 1.7 mM NaCl, 81 μM H3BO3,
6 μM KI, 27 μM MnSO4, 43 μM ZnSO4, 4 μM CuSO4, 31 μM FeCl3, 12 μM
Na2MO4) including leucine (60 mg/L) and lysine (50 mg/L) and grown
at 30 °C for 24 h shaking at 120 rpm. An aliquot of 200 μL of the cell
culture was transferred to 5 mL SD medium including lysine (50 mg/L)
at 30 °C for 24 h. The 5 mL pre-culture was used to inoculate 50 mL of
the same medium and grown at 30 °C for 24 h. The 50 mL culture was
used to inoculate 2 L of YP medium (1% (w/v) yeast extract 2% (w/v)
casein peptone 2% (w/v)) with 3% (v/v) glycerol and 0.5% (w/v)
glucose to an OD450 = 0.1. The 2 L culture was incubated at room
temperature until OD450 = 2.5. Half of the culture (1 L) was incubated
at 15 °C and the other half at 30 °C. After 30 min, the two cultures were
each induced with 110 mL 20% (w/v) galactose dissolved in YP
medium containing 3% (w/v) glycerol and no glucose. 50 mL samples
were harvested at 0, 24, 48, 72, 96, and 120 h after induction by
centrifugation at 4000 g for 20 min. Cells were lysed and crude mem-
branes were isolated at each time point (see below). The GFP fluores-
cence of 25 μg crude membranes was measured for each timepoint in a
spectrofluorimeter (Fluoroskan Ascent, Thermo Scientific). GFP was
exited at 485 nm and emission was measured at 520 nm. GFP fluores-
cence was converted to pmol hNHE1/hGHR from a standard curve
generated from purified GFP mixed with yeast membranes as estab-
lished in [42].
2.4. Crude membrane isolation
1 g yeast cells were mixed with 4 ml glass beads and 1 mL ice cold
Lysis buffer (25 mM Imidazole 1 mM EDTA, 1 mM EGTA, 0.5 M KCl, 5%
(v/v) glycerol, pH 7.5) containing 1 mM PMSF and 1 μg/ml of leu-
peptine, pepstatin and chymostatin (LPC) in a 15 mL Falcon tube. The
Falcon tube was vortexed at max speed for 1 min and left on ice for
1 min. This was repeated 9 times. The lysed suspension was transferred
to a new 15 mL Falcon tube and the beads were washed with 8 mL ice
cold Lysis buffer. The suspension was centrifuged at 1000 g for 10 min
at 4 °C. The supernatant was ultracentrifuged at 40,000 RPM in a 70Ti
rotor for 1.5 h. Crude membranes were resuspended in 0.6 mL Lysis
buffer containing freshly added PMSF and LPC and subsequently stored
at −80 °C. Protein concentrations in crude membranes were de-
termined by BCA assay [49] following manufacturers' specifications
(Sigma, USA) and using chicken ovalbumin as a standard.
2.5. SDS-PAGE and western blotting
SDS-PAGE analysis of protein, in-gel fluorescence and western
blotting were performed as described in [42]. A mixture of two rabbit
polyclonal anti-GFP-antibodies custom made at Pineda, Germany, was
used to detect the hNHE1-GFP and hGHR-GFP fusion proteins in wes-
tern blots in conjunction with a horse radish conjugated anti-rabbit
secondary antibody (Thermo Fisher Scientific). Chemiluminescence
was detected using Immobilon Western Chemiluminescence HRP Sub-
strate (Millipore ®) and the LAS4000 Imager (GE Healthcare, USA).
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2.6. Live cell imaging
Localization of heterologously expressed GFP-tagged hNHE1 and
hGHR was visualized by GFP fluorescence in whole cells at
1000 × magnification, using a Nikon Eclipse E600 microscope coupled
to an Optronics Magnafire model S99802 camera.
2.7. Detergent screens of hNHE1 and hGHR
Crude membranes were incubated in 25 mM Tris-HCl, 10 mM
Imidazole, 0.5 M NaCl, 10% (w/v) glycerol, pH 7.5, supplemented with
1 mM PMSF and 1 μg/ml leupeptin, chymostatin and pepstatin, respec-
tively, at a protein:detergent:CHS ratio of 1:3:1. The detergents included in
the screen were: Foscholine (FC)-12, n-dodecylphosphocholine; FC-13, n-
Tridecylphosphocholine; FC-14, n-Tetradecylphosphocholine; FC-16, n-
hexadecylphosphocholine; LDAO, Lauryldimethylamine N-oxide; Cymal-5,
5-cyclohexyl-1-pentyl-β-D-maltoside; DDM, n-dodecyl-β-D-maltopyranoside;
DM, n-decyl-β-D-maltopyranoside. The detergents were purchased from
Affymetrix, UK or from Glycon Germany and were of anagrade quality.
Solubilization was performed at 4 °C for 4 h. Solubilized hGHR/hNHE1
protein was separated from un-solubilized cell debris by ultracentrifugation
at 70,000 rpm for 20min at 4 °C in a Beckman Optima ™TLX ultracentrifuge
fitted with an S.N. 96U 826 rotor. To detect fluorescence a spectro-
fluorometer (Fluoroskan Ascent, Thermo Scientific) was used using buffer
as background. Samples were exited at 485 nm and emission measured at
520 nm. The efficiency of solubilization was estimated by dividing the GFP-
fluorescence of the supernatant by the total fluorescence prior to cen-
trifugation.
2.8. Fluorescence-detection size exclusion chromatography
Solubilized crude membranes were separated on a Superose 6
Increase 10/300 GL column in 20 mM Tris-HCl, 150 mM NaCl and
0.03% (w/v) DDM at a flow rate of 0.5 mL/min. The column was
coupled to a Shimadzu Prominence RF-20A fluorescence detector and
elution was followed by excitation at 485 nm and measuring emission
at 520 nm to visualize the elution profile of GFP and GFP-tagged
hNHE1/hGHR.
2.9. Production of hGHR/hNHE1 in the bioreactor
Yeast cells from a glycerol stock were selectively propagated until
saturation of 50 mL of SD medium supplemented with 60 mg/ml leu-
cine and 50 mg/ml lysine. Next day, 1 L of SD medium supplemented
with 50 mg/ml lysine was inoculated with the 50 ml pre-culture. After
overnight growth, the 1 L culture was transferred to 10 L of SD medium
supplemented with 20 mg/L adenine, 20 mg/L arginine, 30 mg/L
leucin, 60 mg/L lysin, 20 mg/L methionine, 20 mg/L tryptophan,
40 mg/L uracil and with 3% (w/v) glucose and 3% (w/v) glycerol as
carbon source and propagated in a 15 L Applikon® bioreactor equipped
with an ADI 1030 Bio Controller connected to a PC running the
BioExpert® software (Applikon, Holland). The initial part of the fer-
mentation was performed at 20 °C. The bioreactor was fed with glucose
to a final concentration of 2% (w/v) when the first amount of glucose
had been metabolized. The pH of the growth medium was kept at 6.0 by
computer-controlled addition of 1 M NH4OH. The shift from growth on
glucose to growth on glycerol was monitored as a decrease in the rate of
NH4OH consumption. At this point the bioreactor was cooled to 15 °C
before induction of recombinant protein production with 1 L of 20%
galactose dissolved in the initial growth medium lacking glucose. Yeast
cells were harvested after 72 h at 2000 g for 10 min at 4 °C and sub-
sequently stored at −80 °C.
2.10. Purification of full length hGHR
100 g of yeast cells with recombinantly expressed hGHR were
resuspended in 100 mL of ice-cold Lysis buffer containing 25 mM
Imidazole 1 mM EDTA, 1 mM EGTA, 10% (v/v) glycerol pH 7.5, 1 mM
PMSF and 1 μg/mL of leupeptine, pepstatin and chymostatin (LPC). The
resuspended cells were divided into 10 mL fractions in 50 mL Falcon
tubes and 15 mL glass beads were added to each fraction. Cells were
lysed by vortex mixing for 1 min, with a 1-min rest period on ice. This
was repeated 10 times for each tube. The glass beads were washed with
400 mL lysis buffer and the lysate was centrifuged at 4 °C at 2000 g for
10 min. The pellet was discarded, and the supernatant was centrifuged
at 40,000 rpm in a 70Ti rotor for 1.5 h. The crude membrane pellet was
resuspended in 40 mL lysis buffer. The crude membranes were solubi-
lized by mixing 250 mL 2× solubilization buffer containing 50 mM Tris
pH 7.5, 1000 mM NaCl, 20 mM Imidazole, 1.2% FC-16, 0.2 mM EDTA,
0.2 mM 0.2 EGTA, 2 mM PMSF, 2 μg/μL LPC with the 40 mL crude
membranes and 210 mL ice-cold 18 MΩ water. The crude membranes
were solubilized for 9 h at 4 °C. Following centrifugation at 40,000 rpm
in a 70Ti rotor for 30 min, the supernatant was transferred to a beaker
containing 2 mL Ni-NTA resin (GE Healthcare, USA), pre-equilibrated
in 1× solubilization buffer and left to equilibrate for 8 h at 4 °C. The
solution was transferred to a plastic column and the flow-through dis-
carded. The column was washed with 100 CV of 1× solubilization
buffer containing 60 mM Imidazole and 0.0053% (w/v) FC-16 and
subsequently eluted using 10× CV 1× solubilization buffer containing
300 mM Imidazole and 0.0053% (w/v) FC-16 and in 1 mL fractions.
Protein yields were quantified by measuring absorbance at 280 nm, and
the seven fractions with the highest absorbance were pooled prior to
reconstitution into nanodiscs.
2.11. Purification of full length hNHE1
100 g of yeast cells with recombinantly expressed hNHE1 were re-
suspended in 100 mL of ice-cold Lysis buffer containing 25 mM
Imidazole 1 mM EDTA, 1 mM EGTA, 10% (v/v) glycerol pH 7.5, 1 mM
PMSF, 1 mM DTT and 1 μg/mL of leupeptine, pepstatin, and chymos-
tatin (LPC). Cell lysis was performed identically to the hGHR protocol
as described above, with the addition of 5 mM DTT. The crude mem-
branes were solubilized by mixing 250 mL 2× solubilization buffer
containing 50 mM Tris pH 7.5, 1000 mM NaCl, 20 mM Imidazole,
0.016% (w/v) FC-16, 0.2 mM EDTA, 0.2 mM EGTA, 2 mM PMSF, 2 μg/
μL LPC, 1 mM DTT with the 40 mL crude membranes and 210 mL ice-
cold 18 MΩ water. Crude membranes were solubilized for 4 h at 4 °C.
Following centrifugation at 40,000 rpm in a 70Ti rotor for 30 min at
4 °C, the supernatant was transferred to a beaker containing 2 mL Ni-
NTA resin (GE Healthcare, USA), pre-equilibrated in 1× solubilization
buffer and left to equilibrate for 8 h at 4 °C. The solution was trans-
ferred to a plastic column and the flow-through was discarded. The
column was washed with 100 CV of 1× solubilization buffer containing
50 mM Imidazole and 0.0053% (w/v) FC-16 and subsequently eluted
using 10× CV 1× solubilization buffer containing 300 mM Imidazole
and 0.0053% (w/v) FC-16. Protein yields were quantified by measuring
absorbance at 280 nm. Selected fractions were concentrated using a
Millipore 30,000 MWCO spin filter to 0.4 mL and injected onto a
Superose 6 increase 10/300 GL column (GE Healthcare, USA) equili-
brated with 20 mM Na2HPO4/NaH2PO4 (pH 7.4), 150 mM NaCl and
1 mM DTT.
2.12. hGHR incorporation into MSP1D1 nanodiscs
To prepare the lipid stock, POPC (Avanti) dissolved in chloroform
was dried as a thin film in a glass tube using a nitrogen stream. Next,
the lipid film was solubilized in 20 mM Tris, pH 7.5, 100 mM NaCl,
100 mM cholate (cholate buffer) to a final concentration of 50 mM
POPC. hGHR with POPC and MSP1D1 in a final ratio of 1:70:20 was
prepared as follows: hGHR eluted from the Ni-column was concentrated
using a Millipore 30,000 MWCO spin filter to 2 mL and diluted with
20 mM Tris, pH 7.5, 100 mM NaCl, 1× CMC FC-16 to 15 mL, to reach a
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final Imidazole concentration of 40 mM. The sample was then con-
centrated to 2 mL giving a hGHR concentration of 20 μM, and was
mixed with POPC dissolved in cholate buffer and left to incubate on ice
for 15 min. MSP1D1 was added to the mixture, which was then left to
incubate for 5 min on ice prior to adding freshly prepared bio-beads
SM2 (Biorad) (700 μL beads per 1000 μL sample). Bio-Beads bind to
detergent effectively removing them from the system thereby initiating
the reconstitution of hGHR into MSP1D1. The sample was incubated for
12 h at 4 °C on a tilting table. To remove the Bio-Beads, the sample was
transferred into Eppendorf tubes, punching a small hole in the bottom
of each of the Eppendorf tubes with a needle, and centrifuged at 500 g
for 2 min into 15 mL Falcon tubes, thereby leaving the beads dry in the
Eppendorf tubes and the sample in the 15 mL Falcon tubes. The sample
was diluted 4 times in 20 mM Tris, pH 7.5, 100 mM NaCl, and 2 mL
equilibrated Ni-resin was added to the sample. The sample was allowed
to bind to the Ni-resin for 4 h. The sample and Ni-resin were transferred
to a plastic column, and the flow-through containing MSP1D1 discs
without MP was collected. The Ni+-column was washed with 5 CV
20 mM Tris, pH 7.5, 100 mM NaCl, 10 mM Imidazole and then eluted
with 10 mL 20 mM Tris, pH 7.5, 100 mM NaCl, 400 mM Imidazole. The
entire 10 mL were concentrated using a Millipore 30,000 MWCO spin
filter to 0.4 mL and injected onto a Superose 6 increase 10/300 GL
column (GE) equilibrated with 20 mM Tris, pH 7.5, 100 mM NaCl. The
fractions corresponding to the reconstituted hGHR were assessed by
SDS-PAGE.
2.13. MSP1D1 and MSP1E3D1 protein expression and purification
pET28(+) encoding the His-tagged MSP1D1 gene was kindly pro-
vided by Professor Lise Arleth (University of Copenhagen) and the
plasmid for production of MSP1E3D1 was from Addgene. The proteins
were purified using the same protocol. First, the plasmid was trans-
formed into E. coli BL21 (DE3) by adding 1 μL 100 ng/ μL DNA to
100 μL of competent cells and plated on a LB-agar plate containing
100 mg/L kanamycin and grown at 37 °C overnight. The following day,
a single colony was transferred to 10 mL of LB medium containing
100 mg/L kanamycin and grown for 12 h at 37 °C. The next day, the
10 mL cultures were transferred to 1 L medium in a 5 L flask and grown
at 37 °C until the optical density at 600 nm reached 0.6. The culture was
subsequently induced with 1 mM IPTG for 3 h prior to harvesting the
culture at 4000 g. The cells were resuspended in 40 mL buffer A (50 mM
Tris-HCl, pH 8, 300 mM NaCl, 20 mM Imidazole, 6 M GuHCl) and lysed
by sonication on ice for 60 s at 90% amplitude using a UP400S
Ultrasonic Processor. The suspension was centrifuged at 20,000 g for
15 min and the pellet was discarded. 10 mL of Ni-NTA resin (Qiagen,
Germany) equilibrated in buffer A and was added to the supernatant
and incubated for 1 h at room temperature. The supernatant was loaded
onto a plastic column and the flow-through was discarded. The column
was washed in 3 CVs of buffer A, 3 CVs of wash buffer (50 mM Tris-HCl,
pH 8, 300 mM NaCl, 40 mM Imidazole) including 10 mM sodium
cholate, 3 CVs of wash buffer, and protein was eluted in buffer B
(50 mM Tris-HCl, pH 8, 300 mM NaCl, 400 mM Imidazole). Tobacco
etch virus (TEV) protease was added to the protein sample at 1:100
mass ratio, and the mix was dialyzed 100-fold against TEV buffer
(50 mM Tris-HCl, pH 8, 100 mM NaCl, 1 mM EDTA, 1 mM DTT)
overnight at 4 °C, producing N-terminally cleaved MSP1D1/MSP1E3D1
without the His-tag. MSP1D1/MSP1E3D1 was separated from the His-
tagged TEV protease and residual His-tagged MSP1D1/MSP1E3D1 by
adding Ni-NTA resin to the sample. The MSP1D1/MSP1E3D1 sample
was then dialyzed 100-fold in 20 mM Tris-HCl, pH 7.4, 100 mM NaCl
overnight at 4 °C.
2.14. Microscale thermophoresis (MST)
hGHG120R was purified as in [50] and human prolactin (hPRL)
purified as in [51] and were both labeled with NT-647-NHS [52] using
the Monolith NT™ Protein Labeling Kit RED-NHS (NanoTemper Tech-
nologies) for 1 h at room temperature with NT-647-NHS at a molar
ratio of 1:3 in labelling buffer following the protocol. These conditions
favor modification of the N-terminal amino group. Free dye was sepa-
rated from reacted dye using the provided desalting column. The ratio
between fluorophore and protein was 0.8 for hGHG120R and 0.6 for
hPRL. The raw fluorescence change was used to determine the binding
affinity. A two-fold dilution series of monomeric hGHR from 750 nM to
23 pM was prepared in 20 mM Na2HPO4/NaH2PO4 (pH 7.4), 100 mM
NaCl with either 20 nM hGHG120R or 20 nM hPRL in each sample.
hGHG120R was measured in triplicates whereas hPRL was measured
once. Samples were loaded into Monolith NT.115 Premium Capillaries
(NanoTemper Technologies), and thermophoresis and raw fluorescence
signals measured at 25 °C with a light-emitting diode (LED) power of
80% and an infrared (IR) laser power of 100%. For hGHG120R, the
dissociated constant KD was obtained by fitting the data to
Y = Y0 + (YF − Y0) / (2 ∗ [P]total) ∗ (Kd + [P]total + X − sqrt(sqr
(Kd + [P]total + X) – 4 ∗ [P]total ∗ X))), where Y is the measured
fluorescence/MST, X is the ligand, [P]total is the total concentration of
the protein, YF is the estimated end point of the titration and Y0 is the
start point.
2.15. Circular dichroism
Far-UV CD spectra were recorded on 2 μM hNHE1 in 0.0053% FC-
16 and 2 μM hGHR in 0.0053% FC-16. The spectra were recorded on a
Jasco J-810 Spectropolarimeter in a 1 mm Quartz Suprail cuvette
(Hellma) at 20 °C. 5 scans were accumulated from 260 nm to 190 nm
for both NHE1 and GHR. The scan mode was continuous with 20 nm/
min and a data pitch of 0.5 nm. Buffer was recorded identically and
subtracted. The spectra were processes and smoothened (means-
movement methods, convolution 10) and then converted into mean
residue ellipticity values using the formula [θ] = mdeg /
(10 ∗ c ∗ n ∗ l). To calculate the expected secondary structure content in
the absence of a full-length structures, the Nygaard model [53] was
used as the model for NHE1 and the crystal structure of GFP (1GFL)
[54] included. To determine the expected secondary structure content
for hGHR, the crystal structure of hGHR [23] ECD, the NMR structure of
the TMD [55], characterization of the disordered ICD by CD and NMR
spectroscopy [29] and GFP (1GFL) [54] was used. To determine the
secondary structure for the purified hNHE1 and hGHR the CD data was
analyzed by BeStSel [56] using standard settings.
3. Results
3.1. Prevalence of disordered tails in human MPs
We applied bioinformatics to quantify the occurrence of N- and C-
terminal IDRs in human MPs. The database we used contains 5308 anno-
tated α-helical MP sequences with high likelihood (>98%) of being of
human origin [43]. The sequences were analyzed using Disopred3 [44] and
the histograms in Fig. 2 categorize the MP proteome with respect to length
and position of the IDR. We find that ~22% of the MPs do not have a
disordered N-terminal longer than five residues (Fig. 2A) and ~51% do not
have a disordered C-terminal longer than five residues (Fig. 2B). However,
when we combine these, only ~12% of the human MPs are completely
without terminal IDRs (<5 residues) (Fig. 2C). In fact, MPs with a dis-
ordered N-terminal tail longer than 25 residues account for ~35% of the
MPs with an average length of 54 residues. For C-terminal disorder, ~24%
of MPs have IDRs with an average length of 75 residues, allocating as much
as 2813 MPs to this category. Even more remarkable, roughly 10% of all
human MPs have long disordered regions (>100 residues) in either the N-
or the C-terminal counting over 320 human MPs. With much of the asso-
ciated biology being linked to these disordered regions, it is striking how
disorder is underrepresented in structural studies of MPs. Thus, there is a
need to develop protocols for their isolation and for structural studies.
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3.2. hGHR and hNHE1 localize differently in S. cerevisiae
The most prominent problem reflected in the lack of MP structures
with extensive IDRs, is related to sample preparation. To monitor the
expression of hNHE1 and hGHR in PAP1500 cells, we used the fluor-
escence from the GFP tag. In humans, hNHE1 is expressed in essentially
all cells, localizes to the plasma membrane [12] and is both N- and O-
glycosylated [57]. The hGHR is expressed in almost all cells [58]. It is
synthesized and folded as a precursor protein in the endoplasmic re-
ticulum. hGHR N-glycosylation at five different positions is initiated in
the ER and finalized in the Golgi apparatus [59], resulting in a mature
receptor that is transported to the plasma membrane [60]. In S. cere-
visiae, hNHE1 was primarily present in the plasma membrane (Fig. 3A).
However, in comparison to the expression of free GFP, which dis-
tributed uniformely across the cell cytosol (Fig. 3B), hGHR (Fig. 3C)
accumulated in internal membranes, which could be the result of
overexpression. Furthermore, previous studies in the same expression
system have demonstrated that other MPs purified from intracellular
membranes are functional [36,40,42]. Therefore, we continued opti-
mizing expression levels for both MPs.
3.3. Accumulation is favored at a low temperature
We first used the fluorescence from the GFP-tag to measure the
accumulation of hNHE1 and hGHR in yeast crude membranes at 15 °C
and 30 °C. hNHE1 accumulated to a much higher membrane density at
15 °C compared to 30 °C, reaching a density of 0.7% (w/w) in the crude
membranes 72 h after induction at 15 °C (Fig. 4A). The maximum
amount of accumulated hNHE1 was 3 times higher at 15 °C compared
to 30 °C. The expression of hGHR at 15 °C peaked at a hGHR density of
0.3% (w/w) in crude membranes after approximately 72 h (Fig. 4B).
The accumulation leveled off between 72 and 120 h. hGHR also accu-
mulated to almost the same degree after 24 h at 30 °C as at 15 °C after
72 h. The maximal amount of accumulated hGHR was only 1.2 times
higher at 15 °C compared to 30 °C.
To investigate the temperature dependent accumulation demon-
strated in Fig. 4A and B, we took advantage of the GFP-tag as it has
previously been shown in E. coli that a C-terminal GFP tag only folds
correctly in vivo if the membrane embedded MP fusion partner folds
correctly [61]. This is based on the observations that GFP fluorescence
is preserved after SDS-PAGE analysis and correctly folded GFP only
contributes with 10–15 kDa to the molecular weight of its denatured
MP fusion partner [61]. Fully denatured GFP increases its apparent
SDS-PAGE derived molecular weight to approximately 28 kDa. Thus,
only correctly folded GFP is detected by in-gel fluorescence while both
correctly folded and incorrectly folded GFP can be visualized by wes-
tern blotting. We subsequently analyzed the hNHE1 and hGHR content
in crude membranes by in-gel fluorescence (Fig. 4C and D) and western
blotting using an anti-GFP-antibody (Fig. 4E and F). From the in-gel
fluorescence, it was evident that hNHE1 migrated to the apparent mass
of approximately 110 kDa (Fig. 4C), and that this band correlated with
the band at 110 kDa on the western blot (Fig. 4E). This indicated cor-
rectly folded hNHE1 at both temperatures, but with higher accumula-
tion at 15 °C. A band at approximately 70 kDa was visible in both the in
gel-fluorescence and the western blot, which indicated the presence of a
degradation product, but no larger bands were visible indicating ab-
sence of aggregated hNHE1 (Fig. 4C and E). From the in-gel fluores-
cence and western blotting of hGHR-GFP it was evident from hGHR
expressed at 15 °C that a band with an apparent mass of approximately
125 kDa could be detected, but also a band between the stacking and
running gel (Fig. 4D and F). This may indicate the presence of ag-
gregated hGHR, in accordance with the overexpression observed. The
ratio between correctly folded hGHR and presumed aggregated hGHR
was higher when expressed at 30 °C compared to 15 °C. Thus, both
proteins could be expressed in a folded state in yeast and were present
in the crude membrane fraction when extracted.
3.4. Detergent screens and FSEC screening for optimized purification
To purify hNHE1 and hGHR, identification of a detergent suitable
for solubilization and purification is essential, and considerable effort
should be allocated to screen for conditions that favor both solubility
and homogeneity [62]. To identify conditions that efficiently solubi-
lized hNHE1 and hGHR, we set up a screen with eight different de-
tergents chosen to include different hydrophobicities, critical micelle
concentrations, and non-ionic and zwitterionic moieties (Table 1). The
non-ionic detergents and lauryl-dimethylamine N-oxide (LDAO) were
also included due to their successful contribution to MP crystallography
[63,64]. It is still debated whether Foscholines (FCs) can act as chao-
tropic agents, but recent studies have shown that MPs purified in FCs
can maintain activity [36,42]. The screen was performed at a protein to
detergent ratio of 1:3 in the presence and absence of cholesteryl-hemi-
succinate (CHS) previously shown to increase sample homogeneity
[42]. The solubilization efficiency, which we define as the GFP fluor-
escence post-solubilization divided by GFP fluorescence pre-solubili-
zation, was used to quantify solubility of the MPs in detergent. hNHE1
and hGHR showed better solubilization in the zwitterionic FCs (Fig. 5).
The most effective detergent for both hNHE1 and hGHR was FC-16,
with solubilization efficiencies of approximately 90% and 60%, re-
spectively (Fig. 5).
Solubilization efficiency does not necessarily correlate with the
homogeneity of the sample. Therefore, both hNHE1 and hGHR were
analyzed by fluorescence detected size exclusion chromatography [65]
(FSEC) in all tested detergents with and without CHS (Fig. 5). None of
Fig. 2. Disorder predictions of the human transmembrane proteome. The percentage of sequences in a library of 5308 MPs containing between, 1–5, 6–25, 26–100
and>100 disordered residues are shown for (A) MPs with N-terminal disorder, (B) C-terminal disorder and (C) Either N- or C-terminal disorder. The total number of
MPs for each category is listed above the columns. Disorder was predicted using Disopred3 [44].
N. Kassem, et al. BBA - Biomembranes 1862 (2020) 183272
6
the non-ionic detergents (DM, DDM, Cymal-5) were able to solubilize
NHE1, but only free GFP eluting at approximately 18 ml was visible
(Fig. 6A-C). Upon solubilization of hNHE1 in zwitter-ionic detergents
(LDAO, FC-12, FC-13, FC-14, FC-16), a peak at an elution volume at
approximately 15 ml was observed corresponding to recombinantly
expressed hNHE1 (Fig. 6D-H). Compared to all tested detergents, FC-16
was most effective both in regard to solubilization and homogeneity of
hNHE1. The hGHR was also mainly soluble in the zwitter-ionic de-
tergents and the homogeneity of the recombinantly expressed hGHR
was, similarly to hNHE1, optimal in FC-16 (Fig. 6I-P). The effect of
adding CHS was for both hNHE1 and hGHR a decrease in the amount of
solubilized MP. However, as seen by Fig. 7A-D, and Fig. 7I-L, the ad-
dition of CHS resulted in larger peaks at an elution volume of ap-
proximately 15 ml, but it was not shown to have significant effects for
the FCs. Therefore, it was chosen not to use CHS for purification and
continue with FC-16 for solubilization.
3.5. Circular dichroism shows folding of the recombinant MPs
The C-terminal His10-tag was exploited for Ni-affinity chromato-
graphy immediately after solubilization of both hGHR and hNHE1 in
FC-16. To determine the purity of hGHR and hNHE1, we separated the
elution by SDS-PAGE and visualized the hGHR and hNHE1 content by
in-gel fluorescence and subsequently by Coomassie staining (Fig. 7A).
This showed that the purity after Ni-affinity chromatography was high
as no or only few non-fluorescent bands were visible. To further purify
hGHR and hNHE1, a Superose 6 increase 10/300 SEC column (GE
Healthcare) was used (Fig. 7B). The SEC analysis revealed that the Ni-
affinity chromatography purified samples of hNHE1 and hGHR were
homogenous in FC-16 (Fig. 7B). After SEC, the protein purity was high
and even fewer non-fluorescent bands were visible after Coomassie
staining. Furthermore, we calculated the purity of the individual frac-
tions during the purification by calculating the amount of GFP tagged
protein from the GFP standard curve and comparing with the amount of
purified protein as determined by the BCA assay (Table 2). Table 2
shows that we purified 0.59 mg hNHE1 per liter of cell culture and
0.30 mg hGHR per liter of cell culture with purities of 84% and 88%,
respectively. As some fluorescent bands are still present suggesting a
minor population of degradation products, the purity may be slightly
overestimated. Still, since IDPs bind less Coomassie than BSA [66,67]
the content of full-length GHR is underestimated.
However, as FC-16 is not the most commonly used detergent for
extraction of MPs from crude membranes, the possibility of unfolding of
hNHE1 and hGHR exists. We therefore applied far-UV circular di-
chroism (CD) spectroscopy to verify that the purified proteins attain the
expected content of secondary structures (Fig. 7C). The CD spectra re-
vealed that NHE1 primarily contains an α-helical secondary structure
with minima at 208 nm and 222 nm in line with the suggested model
[68] (Fig. 7C, left). From the solved partial structures of hGHR [23,24],
we expect a combination of β-sheet secondary structures and disorder,
which is confirmed by the CD spectrum (Fig. 7C, right). Furthermore,
preservation of the fluorescence from the C-terminal GFP tag strongly
supports that both hNHE1 and hGHR are folded. To further substantiate
this, we used BeStSel [56] to extract the secondary structure content
from the experimental CD data and compared this to expected sec-
ondary content from available models and crystal structures (see
Materials and methods), Table 3 and Fig. 7C. In the comparison, it is
evident that the α-helix content of hNHE1 obtained from the model
(27%) fits well with the extracted values from the CD data (23%). The
model also included 11% β-sheet structures, which fits well with 9%
from the GFP tag. For GHR, and despite the contribution from aromatic
exiton coupling in the ECD of the hGHR to the far-UV CD spectrum, the
α-helix content in hGHR from the model (8%) again fits well with the
extracted values from the CD data (11%). The β-sheet content from the
CD data (22%) had a slightly larger discrepancy (29%), which could be
attributed to the aromatic exiton coupling from the ECD.
RHGh1EHNh
CA
GFP
B
Fig. 3. Live cell imaging of yeast cells producing hNHE1, hGHR or GFP. (A) S. cerevisiae cells producing hNHE1-TEV-GFP-His10, (B) free GFP or (C) hGHR-TEV-GFP-
His10. S. cerevisiae cells were grown at room temperature in expression medium and induced for 72 h at 15 °C as described in Materials and methods. GFP and DIC
images are shown pairwise.
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Fig. 4. Accumulation of hNHE1-TEV-GFP-His10 and hGHR-TEV-GFP-His10 in S. cerevisiae crude membranes during production at 15 °C or 30 °C. (A, B) S. cerevisiae
cells were grown at room temperature until OD450 = 2.5 and the cultures were divided in two. One half was transferred to 15 °C (blue) and the other was transferred
to 30 °C (red). After thermo-equilibration hNHE1 or hGHR production was initiated by the addition of 2% galactose. Crude membranes were isolated from cells at 0,
24, 48, 72, 96 and 120 h after induction and fluorescence was measured in 25 μg crude membranes. This was converted to pmol hNHE1-GFP fusion (A) or pmol
hGHR-GFP fusion (B) per mg protein in the crude membranes as described in Materials and methods. This was subsequently converted to the percentage (w/w) of
hNHE1 or hGHR in the crude membranes. The molecular weight of the TEV-GFP-His10 was not included in the later calculation. (C, D) From each timepoint at both
15 °C and 30 °C 25 μg crude membranes were analyzed by SDS-PAGE for both (C) hNHE1 and (D) hGHR and were visualized by in-gel fluorescence. (E, F) After
fluorescence detection, the MPs were blotted onto a PVDF membrane and both (E) hNHE1 and (F) hGHR were visualized with an anti-GFP antibody. (For inter-
pretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Table 1
Properties of used detergents.a
Detergent Ionic state Molecular weight (g/mol) Aggregation number CMC (H2O)
DM Non-ionic 482.6 ~69 1.8 mM (0.087% (w/v))
DDM Non-ionic 510.6 ~149 0.17 mM (0.0087% (w/v))
CYMAL5 Non-ionic 494.5 ~47 5 mM (0.12% (w/v))
LDAO Zwitter-ionic 229.4 ~76 1–2 mM (0.023–0.046% (w/v))
FC12 Zwitter-ionic 351.5 ~54 ~1.5 mM (0. 047% (w/v))
FC13 Zwitter-ionic 365.5 ~87 ~0.75 mM (0.027% (w/v))
FC14 Zwitter-ionic 379.5 ~108 ~0.12 mM (0.0046% (w/v))
FC16 Zwitter-ionic 407.5 ~178 ~0.013 mM (0.00053% w/v)
a Aggregation numbers and CMCs taken from http://www.anatrace.com
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In conclusion, we present a protocol that is able to produce intact
MPs with large disordered intracellular domains to homogeneity and in
adequate amounts for structural analyses. To enable such studies, we
proceeded to investigate if reconstitution into nanodiscs from FC-16
would be feasible.
3.6. Reconstitution of hGHR and hNHE1 into nanodiscs
Incorporation of MPs into nanodiscs has emerged as a reliable
technique for studying MPs in a more native-like lipid bilayer en-
vironment void of detergents and in solution for both cryo-EM and
solution scattering techniques such as SAXS and SANS [69–72]. What
these techniques have in common is that they allow studies of MPs in
solution and reconstituted from the conventional golden standard de-
tergent, DDM. In this study, DDM was not an option due to the low
solubility of both hGHR and hNHE1 and instead we used FC-16. The
most structurally characterized and utilized MSP for nanodisc recon-
stitution is the MSP1D1 [73] and the most abundant lipids in the
plasma membrane are the phospholipids. POPC is a synthetic phos-
pholipid that is typically used for nanodisc formation [71,73]. We
therefore chose this combination for reconstitution. The reason for
choosing nanodiscs was two-fold. First, nanodiscs are readily available
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Fig. 6. Fluorescence-detection size exclusion chromatography (FSEC) of hNHE1 (A-H) and hGHR (I-P). FSEC was performed to evaluate the quality of solubilized
hNHE1 and hGHR. Detergent solubilized hNHE1 and hGHR were run on a Superose 6 increase 10/300 GL column as described in Materials and methods. FSEC
profiles of solubilized hNHE1 and hGHR in DM, DDM, Cymal-5, LDAO, FC-12, FC-13, FC-14 and FC-16 in the absence and presence of CHS. Fluorescence was
normalized to the peak value in each profile. The void volume is approximately at 8 ml. The peak at approximately 18 ml is GFP liberated from the fusion protein.
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Fig. 7. Purification of hNHE1 and hGHR. (A) hNHE1 (left) and hGHR (right) were purified by Ni-affinity chromatography (lane: IMAC) and subsequently SEC (lane:
SEC) and visualized by both Coomassie staining and in-gel fluorescence. (B) SEC analysis of Ni-affinity chromatography purified hNHE1 (left) and Ni-affinity
chromatography purified hGHR (right). (C) Far-UV CD spectroscopy analysis of 1 μM hNHE1 (left) hNHE1 and 1 μM hGHR (right). Red dashed lines represent BeStSel
analyses of secondary structure content. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Table 2
Purity and yield for hNHE1 and hGHR per 1 L cell culture/12 g cells.
Samples IMAC yield from
A280 (mg)
SEC yield from
A280 (mg)
SEC yield from
fluorescence (mg)
Purity
hNHE1 1.1 0.70 0.59 84%
hGHR 0.48 0.34 0.30 88%
Table 3
Secondary structure content from model and from far-UV CD.
α-helix (%) β-strand (%) Turns and others (%)
hNHE1CD 27 11 62
hNHE1model 23 9.0 68
hGHRCD 11 29 60
hGHRmodel 8 22 70
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and constitute a system for which several different protocols have been
published. Second, and more importantly, as membrane proteins with
long IDRs are likely to be investigated by small angle scattering tech-
niques, nanodiscs form more homogeneous samples preparations than
e.g. SMALPS and saposin, and the small angle scattering parameters
from the discs are readily obtained [71,72]. As hNHE1 forms a dimer
with each monomer consisting of 12 TM helices [12], the most used
nanodisc, the MSP1D1, is not a suitable scaffold and larger scaffolds
would be needed. An extended MSP has been developed, the
MSP1E3D1 [32], which should be adequate for 12 and 24 TM α-helices
and this was used for testing reconstitution of hNHE1. For hGHR, with
its single pass architecture, we used the conventional MSP1D1 for re-
constitution.
To incorporate hGHR in MSP1D1, we mixed purified hGHR with
POPC and sodium cholate to form mixed micelles prior to adding
purified MSP1D1 from E. coli and detergent-extracting Bio-Beads. After
incubation, IMAC was used to separate the loaded hGHR MSP1D1 discs
from the empty MSP1D1 discs. SEC purification of loaded and unloaded
discs was performed separately on a Superose 6 increase 10/300
column (Fig. 8A,B). This revealed that hGHR in MSP1D1 elutes at
10–14 mL, which was confirmed by SDS-PAGE, indicating that recon-
stitution was successful (Fig. 8C). The empty MSP1D1 discs were run as
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Fig. 8. Incorporation of hGHR into MSP1D1 nanodiscs. (A) SEC purification of hGHR loaded MSP1D1 nanodiscs. (B) SEC purification of empty MSP1D1 nanodiscs.
(C) SDS-PAGE analysis of hGHR incorporated into MSP1D1 and empty MSP1D1 discs (D) MST of hGH-G120R binding to hGHR in a nanodisc. (E) MST of hPRL
binding to hGHR in a nanodisc.
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reference (Fig. 8B). We also tested the incorporation of hNHE1 into a
larger nanodisc using MSP1E3D1. We initially tried reconstitution in
this nanodisc using the same lipid solution as with hGHR, but hNHE1
aggregated upon detergent removal. We then attempted to use
POPC:POPS mixtures, but the hNHE1 sample still aggregated upon
detergent removal. To mimic the native membrane even further we
attempted a mixture of soybean polar lipid extracts (Avanti, USA) and
CHS. However, no incorporation was observed. Thus, we were not able
to incorporate hNHE1 into nanodiscs.
To finally assess the functionality of the nanodisc-reconsituted GHR,
we applied MST and the fluorescently labeled receptor antagonist, the
hGH-G120R. We used the antagonist as opposed to an agonist, with the
purpose of not introducing dimers across the discs and because the
agonist at high concentration would lead to monomerization, compli-
cating the fluorescent readout. With this experimental approach, the
dissociation constant between hGHG120R and hGHR(MSP1D1) was de-
termined to be KD = 60 ± 24 nM (Fig. 8D). The affinities of hGH for
hGHR-ECD have previously been reported as 1.2 nM and 3.5 nM for
binding to the first and the second site of hGH, respectively, and the
affinity for hGHG120R is known to be highly similar or slightly lower
[74,75]. As negative control, we used hPRL, which cannot activate
hGHR in vivo, and indeed, we observed no binding (Fig. 8E). Thus, the
nanodisc-reconstituted, yeast-produced intact full length hGHR is
binding competent.
Functional analysis is the ultimate test of any purified protein.
However, as hNHE1 exchanges one proton for one sodium ion, it is
electrically neutral and the measurements of activity require recon-
stitution into liposomes and co-establishment of a proton-generating
system, which is beyond the scope of the current work (see e.g. [76]).
The correlation of the secondary structure content with an existing
model, the homogeneity of the elution peak from SEC, as well as the
low FC16 concentration used in the extraction, suggest that hNHE1 is
correctly folded.
In conclusion, we were able to produce intact full length hGHR and
incorporate it into MSP1D1 nanodiscs, which on a larger-scale pro-
duction will enable future structural studies using either SAXS or SANS
and potentially also cryo-EM. NHE1 was produced to homogeneity and
was helical and with an intact disordered tail, yet incorporation of
NHE1 in the largest available nanodisc, MSP1E3D1, was not achieved.
4. Discussion
Because of the lack of structural characterization of MPs containing
intra- and extra cellular intrinsically disordered domains, this work
aimed at providing a protocol for purification and incorporation of
intact MPs with disordered regions into nanodiscs. This protocol suc-
cessfully led to the purification of two highly different MPs, the hNHE1
and the hGHR. The protocol is straightforward and will help improve
the ability to produce and study MPs also with long disordered tails by
means of biochemical and biophysical techniques and thereby increase
the rate by which MPs are structurally characterized. We employed the
two widely different human MPs, NHE1 and hGHR and produced them
in S. cerevisiae. hNHE1 was selected because no high-resolution struc-
ture of hNHE1 or any eukaryotic homologs exists. A crystal structure of
the GHR-ECD [23], NMR structures of the GHR-TMD [55] and NMR
characterization of the C-terminal disordered tail [29] are available, but
no experimentally based full-length structure is available for GHR or
any other cytokine receptor.
We produced hNHE1 and hGHR with a C-terminal GFP tag to sim-
plify optimization of expression and purification and also exploited GFP
as a folding reporter [61]. A potential disadvantage of using GFP
fluorescence to quantify recombinant MP accumulation is that fluor-
escent degradation products contribute to the measured GFP fluores-
cence. hNHE1 produced in S. cerevisiae was mainly located in the
plasma membrane. However, hGHR was mainly located in intracellular
membranes as detected by in vivo fluorescence microscopy. Studies of
membrane proteins purified from internal membranes of S. cerevisiae
have suggested that they are functional [36,40,42]. We also observed
that both hNHE1 and hGHR produced at 15 °C accumulated with the
expected molecular weights and that degradation was minor (Fig. 3)
and that they maintained a folded structure when purified. Fluores-
cence, therefore, originates from accumulation of intact hNHE1 and
hGHR.
Identifying suitable detergents for purification of MPs involves labor
intensive screening, as a single detergent that fits all MPs does not exist.
The detergent screen on hNHE1 and hGHR revealed that they are only
soluble in zwitter-ionic detergents such as LDAO and FCs (Fig. 6), and
not in the frequently used detergent DDM. High solubilization effi-
ciency is of course a high priority, but it is even more important that the
solubilization results in a homogenous MP sample. This was assayed by
FSEC analysis of hNHE1 and hGHR using all tested detergents in the
absence and presence of CHS (Fig. 7). Both hNHE1 and hGHR were
homogenous in the FCs, and since FC-16 solubilized the most protein,
this was used for purification (Fig. 7). Both hNHE1 and hGHR were
isolated by Ni-affinity chromatography and subsequent SEC to high
purity and homogeneity. Furthermore, both proteins remained folded
as evaluated by CD spectroscopy.
Recent cryo-EM, SAXS and SANS studies of MPs have emphasized
the importance of nanodiscs as a tool for in vitro studies of MPs under
native-like conditions [69–72]. Indeed, even with a long disordered tail
of> 350 residues, it was possible to incorporate hGHR into MSP1D1.
Because of the size of hNHE1 - a 12 TM-helical MP that forms dimers in
its native state - we attempted to incorporate hNHE1 into larger na-
nodiscs using MSP1E3D1. Unsuccesful attempts were made both using
simple lipid solutions such as just POPC, but also in POPC:POPS mix-
tures and a mixture of soybean polar lipid extracts and CHS. As the C-
terminal disordered tail of hNHE1 has lipid binding domains [12,77],
the larger nanodisc may not have been large enough to allow solubi-
lization via membrane interaction. It is therefore possible that a C-
terminally truncated version of hNHE1 would be amenable for recon-
stitution into MSP1E3D1, but we did not pursue this further. A better
solution which will allow studies of the intact NHE1 with its tail may be
to use an even larger nanodisc, which is currently not available. Once
these emerge, NHE1 would be a good first candidate for their appli-
cation.
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